$MRVL

Koopmans Chris sold $2.8M of MRVL (indirect holdings)

Koopmans Chris (President and COO) sold 10,000 indirectly-held shares of Marvell Technology, Inc. (MRVL) at $281.92 ($2.82M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Koopmans Chris
Published Jul 1, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MRVL
Neutral
medium confidence
Mentioned
$MRVL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRVLNeutralLow
01

Why it matters

The disclosure updates the record of insider activity (open-market sale) but does not introduce new company fundamentals or guidance.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but provides no context on total insider exposure, other concurrent sales, or whether the plan size/timing is typical.

Relevance 5/10Novelty 5/10Timing: filed 2026-07-01 (after-hours) for an insider sale executed the same day

Background

This is an SEC Form 4 insider transaction disclosure for Marvell Technology, Inc. (MRVL).

Company-level read

Ticker impact

$MRVLNeutralMedium confidence
Context

Marvell’s President and COO Chris Koopmans sold 10,000 shares in an open-market transaction at $281.92 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling. The article contains no new operational, financial, or regulatory catalyst.

Market effects

Minimal; this is company-specific insider transaction data with no disclosed sector-wide catalyst.

Minimal; no macro/regional linkage beyond general US equity sentiment.

Minimal; no international deal/regulatory development mentioned.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may ignore it for directional bias.

Key entities

  • Marvell Technology, Inc.

    Subject of the Form 4 insider transaction; President and COO sold shares under a 10b5-1 plan.

  • Koopmans Chris

    President and COO; executed an open-market sale of 10,000 shares at $281.92 on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRVLMed

Should You Sell Your Marvell Stock Now That Higher Forecasts Are Not Enough?

Marvell Technology (MRVL) raised its revenue outlook to $18B for fiscal 2028, but its stock fell 16.4% over three months. The company trades at a P/E of 88.0, significantly higher than the S&P 500's 22.5. Management expects revenue growth of about 50% in fiscal 2028, with major gains from an AI chip deal anticipated in fiscal 2029 and beyond.

$MRVLMed

Marvell Technology (MRVL) Shares Skyrocket, What You Need To Know

Marvell Technology (MRVL) shares rose 6.1% after announcing 2nm optical interconnect demonstrations for AI data centers. Morgan Stanley raised its price target to $268. Shares closed at $257.14, up 5.5%. The company is up 187% YTD but 19% below its 52-week high. Positive macroeconomic factors and sector-wide AI chipmaker rally contributed to the surge.

$MRVLMed

Why Marvell Stock Rallied Today

Marvell Technology (MRVL) shares rose 6% on Monday after announcing a 2nm optical interconnect demo for AI data centers. Morgan Stanley raised its price target to $268, citing potential $40B+ fiscal 2030 revenue. MRVL grew revenue 42% to $8.2B in fiscal 2026, forecasting 45% and 50% growth for fiscal 2027 and 2028, respectively.